证券记录 · 已归档季度
GLUE
Monte Rosa Therapeutics, Inc. · Healthcare · Biotechnology
9被追踪持有人
-3Δ持有人
9.96M持有股份
$46.20M报告持仓市值
+1新建仓位
−4清仓
动量输入（同类管理人）：
持有人广度 -25.0% ·
股份流向 -15.7% ·
净新建仓位 -20.0%
— 公式
广泛派发 — 持股数量下降且持有人减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q1 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | -3 | 40.75M | $985.52M | +5 | −8 |
| Q1 2026 | 84 | +11 | 37.29M | $613.27M | +14 | −3 |
| Q4 2025 | 73 | -1 | 26.21M | $411.01M | +1 | −2 |
| Q3 2025 | 18 | +2 | 20.02M | $148.32M | +2 | — |
| Q2 2025 | 13 | +1 | 20.51M | $92.50M | +1 | — |
| Q1 2025 | 9 | -3 | 9.96M | $46.20M | +1 | −4 |
| Q4 2024 | 12 | +2 | 11.82M | $82.01M | +2 | — |
| Q3 2024 | 9 | +2 | 9.48M | $50.23M | +2 | — |
| Q2 2024 | 7 | — | 8.29M | $30.99M | — | — |
持有人 · Q1 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 6.64M | -6.6% | $30.83M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 6.64M | -6.6% | $30.83M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (被动) | 1.00M | -3.1% | $4.66M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (被动) | 1.00M | -3.1% | $4.66M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (被动) | 801.26K | -25.6% | $3.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Marshall Wace ✦ | 371.74K | -25.6% | $1.72M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Marshall Wace ✦ | 371.74K | -25.6% | $1.72M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Marshall Wace ✦ | 371.74K | -25.6% | $1.72M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | Millennium Management ✦ | 330.47K | +612.7% | $1.53M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 229.54K | 新增 | $1.07M | 0.0% | New | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 229.54K | 新增 | $1.07M | 0.0% | New | 1 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 229.54K | 新增 | $1.07M | 0.0% | New | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 229.54K | 新增 | $1.07M | 0.0% | New | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 229.54K | 新增 | $1.07M | 0.0% | New | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 223.13K | -20.0% | $1.04M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Wellington Management ✦ | 187.73K | -15.3% | $871,072 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | Wellington Management ✦ | 187.73K | -15.3% | $871,072 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Renaissance Technologies ✦ | 164.10K | -33.2% | $761,424 | 0.0% | ▼ Trim | 4 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| AQR Capital Management | $1.07M | 0.0% |
| AQR Capital Management | $1.07M | 0.0% |
| AQR Capital Management | $1.07M | 0.0% |
| AQR Capital Management | $1.07M | 0.0% |
| AQR Capital Management | $1.07M | 0.0% |
已清仓
| Citadel Advisors | $5.40M | 曾为 0.0% |
| Norges Bank | $3.09M | 曾为 0.0% |
| D. E. Shaw & Co. | $486,591 | 曾为 0.0% |
| Point72 Asset Management | $1,736 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 188 持有人, 86.88M 股份, $1.31B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q1 2025 ·
方法论 ·
通过API获取此数据